Author Archives: Margarida Azevedo

Amgen to Present New Data on Kyprolis, a Multiple Myeloma Treatment, at EHA 2016

Amgen announced it will present new data on its cancer portfolio at the 21st Congress of the European Hematology (EHA) Association taking place next month in Copenhagen. The data will include recent evaluations of the drugs Blincyto (blinatumomab), Kyprolis (carfilzomib), Aranesp (darbepoetin alfa) and Nplate (romiplostim) in treating a range of malignancies, such as multiple…

Ongoing Phase 3 Study Finds Daratumumab Improves Survival in Advanced Multiple Myeloma Patients

Genmab has announced positive results from its Phase 3 POLLUX study investigating the efficacy of daratumumab, in combination with lenalidomide and dexamethasone, to treat patients with relapsed or refractory multiple myeloma, compared to lenalidomide and dexamethasone alone. The ongoing trial met its primary endpoint, with treated patients demonstrating improved progression-free survival, indicating that the…

Researchers Develop New Animal Model of Multiple Myeloma

Researchers in the Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have developed a new animal model of multiple myeloma, which will hopefully allow researchers to better understand the pathology and physiology involved in the development of the disease and test new potential therapeutic agents. The…

MedImmune’s Antibody Therapy Seen to Effectively Reduce Cancer Stem Cells in Most Newly Diagnosed Multiple Myeloma Patients

A research team led by William Matsui, MD, and Carol Ann Huff, MD, with the Johns Hopkins Kimmel Cancer Center, has found that MedImmune’s novel MEDI-551 antibody treatment effectively decreased the number of cancer stem cells, which drive the growth of cancer, in most patients with recently diagnosed multiple myeloma. Study results will be…